Which are the optimal thromboprophylaxis strategies for hospitalized patients with COVID-19? current controversies

Mateo Porres-Aguilar1, Debabrata Mukherjee2, S Claudia Didia1

  • 1Department of Internal Medicine, Divisions of Hospital and Adult Clinical Thrombosis Medicine, Texas Tech University Health Sciences Center and Paul L. Foster School of Medicine, El Paso, TX, USA.

Vascular
|September 9, 2022
PubMed

Insights

COVID-19 increases the risk of venous thromboembolism (VTE) in hospitalized patients. This review examines thromboprophylaxis strategies and discusses anticoagulation controversies, especially for moderate COVID-19 cases.

Area of Science:

  • Internal Medicine
  • Cardiology
  • Pulmonology

Background:

  • COVID-19 is a significant risk factor for venous thromboembolism (VTE).
  • Hospitalized patients with moderate to severe/critical COVID-19 face elevated VTE risks.
  • Understanding optimal VTE prevention is crucial for patient outcomes.

Purpose of the Study:

  • To review current thromboprophylaxis strategies for COVID-19 patients.
  • To discuss controversies surrounding anticoagulation in VTE prevention.
  • To offer a perspective on managing VTE risk in moderately ill COVID-19 patients.

Main Methods:

  • Literature review of emerging data on thromboprophylaxis.
  • Analysis of current anticoagulation guidelines and practices.
  • Discussion of clinical controversies and expert opinion.

Main Results:

  • COVID-19 is strongly associated with increased VTE risk.
  • Various thromboprophylaxis strategies are under investigation.
  • Debate exists regarding the optimal intensity and duration of anticoagulation, particularly in moderate cases.

Conclusions:

  • Effective VTE prophylaxis is essential for hospitalized COVID-19 patients.
  • Further research is needed to clarify optimal anticoagulation strategies.
  • Personalized approaches may be necessary for managing VTE risk in different COVID-19 severity groups.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
37
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
618
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
22
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
861